Skip to main content
Erschienen in: European Radiology 9/2016

03.12.2015 | Hepatobiliary-Pancreas

Identification of Imaging Predictors Discriminating Different Primary Liver Tumours in Patients with Chronic Liver Disease on Gadoxetic Acid-enhanced MRI: a Classification Tree Analysis

verfasst von: Hyun Jeong Park, Kyung Mi Jang, Tae Wook Kang, Kyoung Doo Song, Seong Hyun Kim, Young Kon Kim, Dong Ik Cha, Joungyoun Kim, Juna Goo

Erschienen in: European Radiology | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To identify predictors for the discrimination of intrahepatic cholangiocarcinoma (IMCC) and combined hepatocellular-cholangiocarcinoma (CHC) from hepatocellular carcinoma (HCC) for primary liver cancers on gadoxetic acid-enhanced MRI among high-risk chronic liver disease (CLD) patients using classification tree analysis (CTA).

Methods

A total of 152 patients with histopathologically proven IMCC (n = 40), CHC (n = 24) and HCC (n = 91) were enrolled. Tumour marker and MRI variables including morphologic features, signal intensity, and enhancement pattern were used to identify tumours suspicious for IMCC and CHC using CTA.

Results

On CTA, arterial rim enhancement (ARE) was the initial splitting predictor for assessing the probability of tumours being IMCC or CHC. Of 43 tumours that were classified in a subgroup on CTA based on the presence of ARE, non-intralesional fat, and non-globular shape, 41 (95.3 %) were IMCCs (n = 29) or CHCs (n = 12). All 24 tumours showing fat on MRI were HCCs. The CTA model demonstrated sensitivity of 84.4 %, specificity of 97.8 %, and accuracy of 92.3 % for discriminating IMCCs and CHCs from HCCs.

Conclusions

We established a simple CTA model for classifying a high-risk group of CLD patients with IMCC and CHC. This model may be useful for guiding diagnosis for primary liver cancers in patients with CLD.

Key Points

Arterial rim enhancement was the initial splitting predictor on CTA.
CTA model achieved high sensitivity, specificity, and accuracy for discrimination of tumours.
This model may be useful for guiding diagnosis of primary liver cancers.
Literatur
1.
Zurück zum Zitat Sorensen HT, Friis S, Olsen JH et al (1998) Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 28:921–925CrossRefPubMed Sorensen HT, Friis S, Olsen JH et al (1998) Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 28:921–925CrossRefPubMed
2.
Zurück zum Zitat Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA (2005) Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 128:620–626CrossRefPubMed Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA (2005) Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 128:620–626CrossRefPubMed
3.
Zurück zum Zitat Yamamoto S, Kubo S, Hai S et al (2004) Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci 95:592–595CrossRefPubMed Yamamoto S, Kubo S, Hai S et al (2004) Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci 95:592–595CrossRefPubMed
4.
Zurück zum Zitat Jarnagin WR, Weber S, Tickoo SK et al (2002) Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer 94:2040–2046CrossRefPubMed Jarnagin WR, Weber S, Tickoo SK et al (2002) Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer 94:2040–2046CrossRefPubMed
5.
Zurück zum Zitat Chantajitr S, Wilasrusmee C, Lertsitichai P, Phromsopha N (2006) Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population. J Hepatobiliary Pancreat Surg 13:537–542CrossRefPubMed Chantajitr S, Wilasrusmee C, Lertsitichai P, Phromsopha N (2006) Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population. J Hepatobiliary Pancreat Surg 13:537–542CrossRefPubMed
6.
Zurück zum Zitat Bruix J, Sherman M, American Association for the Study of Liver D (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022CrossRefPubMedPubMedCentral Bruix J, Sherman M, American Association for the Study of Liver D (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Lieser MJ, Barry MK, Rowland C, Ilstrup DM, Nagorney DM (1998) Surgical management of intrahepatic cholangiocarcinoma: a 31-year experience. J Hepatobiliary Pancreat Surg 5:41–47CrossRefPubMed Lieser MJ, Barry MK, Rowland C, Ilstrup DM, Nagorney DM (1998) Surgical management of intrahepatic cholangiocarcinoma: a 31-year experience. J Hepatobiliary Pancreat Surg 5:41–47CrossRefPubMed
8.
Zurück zum Zitat Valverde A, Bonhomme N, Farges O, Sauvanet A, Flejou JF, Belghiti J (1999) Resection of intrahepatic cholangiocarcinoma: a Western experience. J Hepatobiliary Pancreat Surg 6:122–127CrossRefPubMed Valverde A, Bonhomme N, Farges O, Sauvanet A, Flejou JF, Belghiti J (1999) Resection of intrahepatic cholangiocarcinoma: a Western experience. J Hepatobiliary Pancreat Surg 6:122–127CrossRefPubMed
9.
Zurück zum Zitat Yin X, Zhang BH, Qiu SJ et al (2012) Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol 19:2869–2876CrossRefPubMed Yin X, Zhang BH, Qiu SJ et al (2012) Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol 19:2869–2876CrossRefPubMed
10.
Zurück zum Zitat Sapisochin G, Fidelman N, Roberts JP, Yao FY (2011) Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma. Liver Transpl 17:934–942CrossRefPubMed Sapisochin G, Fidelman N, Roberts JP, Yao FY (2011) Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma. Liver Transpl 17:934–942CrossRefPubMed
11.
Zurück zum Zitat Lee WS, Lee KW, Heo JS et al (2006) Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today 36:892–897CrossRefPubMed Lee WS, Lee KW, Heo JS et al (2006) Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today 36:892–897CrossRefPubMed
12.
Zurück zum Zitat Kadoya M, Matsui O, Takashima T, Nonomura A (1992) Hepatocellular carcinoma: correlation of MR imaging and histopathologic findings. Radiology 183:819–825CrossRefPubMed Kadoya M, Matsui O, Takashima T, Nonomura A (1992) Hepatocellular carcinoma: correlation of MR imaging and histopathologic findings. Radiology 183:819–825CrossRefPubMed
13.
Zurück zum Zitat Maetani Y, Itoh K, Watanabe C et al (2001) MR imaging of intrahepatic cholangiocarcinoma with pathologic correlation. AJR Am J Roentgenol 176:1499–1507CrossRefPubMed Maetani Y, Itoh K, Watanabe C et al (2001) MR imaging of intrahepatic cholangiocarcinoma with pathologic correlation. AJR Am J Roentgenol 176:1499–1507CrossRefPubMed
14.
Zurück zum Zitat Chong YS, Kim YK, Lee MW et al (2012) Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI. Clin Radiol 67:766–773CrossRefPubMed Chong YS, Kim YK, Lee MW et al (2012) Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI. Clin Radiol 67:766–773CrossRefPubMed
15.
Zurück zum Zitat Burns PN, Wilson SR (2007) Focal liver masses: enhancement patterns on contrast-enhanced images—concordance of US scans with CT scans and MR images. Radiology 242:162–174CrossRefPubMed Burns PN, Wilson SR (2007) Focal liver masses: enhancement patterns on contrast-enhanced images—concordance of US scans with CT scans and MR images. Radiology 242:162–174CrossRefPubMed
16.
Zurück zum Zitat Rimola J, Forner A, Reig M et al (2009) Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 50:791–798CrossRefPubMed Rimola J, Forner A, Reig M et al (2009) Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 50:791–798CrossRefPubMed
17.
Zurück zum Zitat Kawamura Y, Ikeda K, Hirakawa M et al (2010) New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma. Hepatol Res 40:1006–1014CrossRefPubMed Kawamura Y, Ikeda K, Hirakawa M et al (2010) New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma. Hepatol Res 40:1006–1014CrossRefPubMed
18.
Zurück zum Zitat Kang Y, Lee JM, Kim SH, Han JK, Choi BI (2012) Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images. Radiology 264:751–760CrossRefPubMed Kang Y, Lee JM, Kim SH, Han JK, Choi BI (2012) Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images. Radiology 264:751–760CrossRefPubMed
19.
Zurück zum Zitat Park HJ, Kim YK, Park MJ, Lee WJ (2013) Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma. Abdom Imaging 38:793–801CrossRefPubMed Park HJ, Kim YK, Park MJ, Lee WJ (2013) Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma. Abdom Imaging 38:793–801CrossRefPubMed
20.
Zurück zum Zitat Choi YS, Rhee H, Choi JY et al (2013) Histological characteristics of small hepatocellular carcinomas showing atypical enhancement patterns on gadoxetic acid-enhanced MR imaging. J Magn Reson Imaging 37:1384–1391CrossRefPubMed Choi YS, Rhee H, Choi JY et al (2013) Histological characteristics of small hepatocellular carcinomas showing atypical enhancement patterns on gadoxetic acid-enhanced MR imaging. J Magn Reson Imaging 37:1384–1391CrossRefPubMed
21.
Zurück zum Zitat Choi JW, Lee JM, Kim SJ et al (2013) Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker. Radiology 267:776–786CrossRefPubMed Choi JW, Lee JM, Kim SJ et al (2013) Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker. Radiology 267:776–786CrossRefPubMed
22.
Zurück zum Zitat Shetty AS, Fowler KJ, Brunt EM, Agarwal S, Narra VR, Menias CO (2014) Combined hepatocellular-cholangiocarcinoma: what the radiologist needs to know about biphenotypic liver carcinoma. Abdom Imaging 39:310–322CrossRefPubMed Shetty AS, Fowler KJ, Brunt EM, Agarwal S, Narra VR, Menias CO (2014) Combined hepatocellular-cholangiocarcinoma: what the radiologist needs to know about biphenotypic liver carcinoma. Abdom Imaging 39:310–322CrossRefPubMed
23.
Zurück zum Zitat Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF (2008) Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 57:1592–1596CrossRefPubMed Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF (2008) Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 57:1592–1596CrossRefPubMed
24.
Zurück zum Zitat Khan SA, Davidson BR, Goldin R et al (2002) Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51(Suppl 6):VI1–VI9PubMedPubMedCentral Khan SA, Davidson BR, Goldin R et al (2002) Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51(Suppl 6):VI1–VI9PubMedPubMedCentral
25.
Zurück zum Zitat Leo Breiman , Jerome Friedman, Charles J. Stone and R.A. Olshen (1984) Classification and Regression Trees. Chapman and Hall/CRC Leo Breiman , Jerome Friedman, Charles J. Stone and R.A. Olshen (1984) Classification and Regression Trees. Chapman and Hall/CRC
26.
Zurück zum Zitat Befeler AS, Hayashi PH, Di Bisceglie AM (2005) Liver transplantation for hepatocellular carcinoma. Gastroenterology 128:1752–1764CrossRefPubMed Befeler AS, Hayashi PH, Di Bisceglie AM (2005) Liver transplantation for hepatocellular carcinoma. Gastroenterology 128:1752–1764CrossRefPubMed
27.
Zurück zum Zitat Marti-Bonmati L, Talens A, del Olmo J et al (1993) Chronic hepatitis and cirrhosis: evaluation by means of MR imaging with histologic correlation. Radiology 188:37–43CrossRefPubMed Marti-Bonmati L, Talens A, del Olmo J et al (1993) Chronic hepatitis and cirrhosis: evaluation by means of MR imaging with histologic correlation. Radiology 188:37–43CrossRefPubMed
30.
Zurück zum Zitat El Malki HO, El Mejdoubi Y, Souadka A et al (2010) Predictive model of biliocystic communication in liver hydatid cysts using classification and regression tree analysis. BMC Surg 10:16CrossRefPubMedPubMedCentral El Malki HO, El Mejdoubi Y, Souadka A et al (2010) Predictive model of biliocystic communication in liver hydatid cysts using classification and regression tree analysis. BMC Surg 10:16CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Thomassin-Naggara I, Toussaint I, Perrot N et al (2011) Characterization of complex adnexal masses: value of adding perfusion- and diffusion-weighted MR imaging to conventional MR imaging. Radiology 258:793–803CrossRefPubMed Thomassin-Naggara I, Toussaint I, Perrot N et al (2011) Characterization of complex adnexal masses: value of adding perfusion- and diffusion-weighted MR imaging to conventional MR imaging. Radiology 258:793–803CrossRefPubMed
32.
Zurück zum Zitat Nunes LW, Schnall MD, Orel SG (2001) Update of breast MR imaging architectural interpretation model. Radiology 219:484–494CrossRefPubMed Nunes LW, Schnall MD, Orel SG (2001) Update of breast MR imaging architectural interpretation model. Radiology 219:484–494CrossRefPubMed
33.
Zurück zum Zitat Jeong HT, Kim MJ, Chung YE, Choi JY, Park YN, Kim KW (2013) Gadoxetate disodium-enhanced MRI of mass-forming intrahepatic cholangiocarcinomas: imaging-histologic correlation. AJR Am J Roentgenol 201:W603–W611CrossRefPubMed Jeong HT, Kim MJ, Chung YE, Choi JY, Park YN, Kim KW (2013) Gadoxetate disodium-enhanced MRI of mass-forming intrahepatic cholangiocarcinomas: imaging-histologic correlation. AJR Am J Roentgenol 201:W603–W611CrossRefPubMed
34.
Zurück zum Zitat Hwang J, Kim YK, Park MJ et al (2012) Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI. J Magn Reson Imaging 36:881–889CrossRefPubMed Hwang J, Kim YK, Park MJ et al (2012) Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI. J Magn Reson Imaging 36:881–889CrossRefPubMed
35.
Zurück zum Zitat Kierans AS, Leonardou P, Hayashi P et al (2010) MRI findings of rapidly progressive hepatocellular carcinoma. Magn Reson Imaging 28:790–796CrossRefPubMed Kierans AS, Leonardou P, Hayashi P et al (2010) MRI findings of rapidly progressive hepatocellular carcinoma. Magn Reson Imaging 28:790–796CrossRefPubMed
36.
Zurück zum Zitat An C, Kim DW, Park YN, Chung YE, Rhee H, Kim MJ (2015) Single Hepatocellular Carcinoma: Preoperative MR Imaging to Predict Early Recurrence after Curative Resection. Radiology 142394 An C, Kim DW, Park YN, Chung YE, Rhee H, Kim MJ (2015) Single Hepatocellular Carcinoma: Preoperative MR Imaging to Predict Early Recurrence after Curative Resection. Radiology 142394
37.
Zurück zum Zitat Yu JS, Chung JJ, Kim JH, Kim KW (2007) Fat-containing nodules in the cirrhotic liver: chemical shift MRI features and clinical implications. AJR Am J Roentgenol 188:1009–1016CrossRefPubMed Yu JS, Chung JJ, Kim JH, Kim KW (2007) Fat-containing nodules in the cirrhotic liver: chemical shift MRI features and clinical implications. AJR Am J Roentgenol 188:1009–1016CrossRefPubMed
38.
Zurück zum Zitat Martin J, Sentis M, Zidan A et al (1995) Fatty metamorphosis of hepatocellular carcinoma: detection with chemical shift gradient-echo MR imaging. Radiology 195:125–130CrossRefPubMed Martin J, Sentis M, Zidan A et al (1995) Fatty metamorphosis of hepatocellular carcinoma: detection with chemical shift gradient-echo MR imaging. Radiology 195:125–130CrossRefPubMed
39.
Zurück zum Zitat Kutami R, Nakashima Y, Nakashima O, Shiota K, Kojiro M (2000) Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol 33:282–289CrossRefPubMed Kutami R, Nakashima Y, Nakashima O, Shiota K, Kojiro M (2000) Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol 33:282–289CrossRefPubMed
40.
Zurück zum Zitat Asayama Y, Nishie A, Ishigami K et al (2015) Distinguishing intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma using precontrast and gadoxetic acid-enhanced MRI. Diagn Interv Radiol 21:96–104CrossRefPubMedPubMedCentral Asayama Y, Nishie A, Ishigami K et al (2015) Distinguishing intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma using precontrast and gadoxetic acid-enhanced MRI. Diagn Interv Radiol 21:96–104CrossRefPubMedPubMedCentral
Metadaten
Titel
Identification of Imaging Predictors Discriminating Different Primary Liver Tumours in Patients with Chronic Liver Disease on Gadoxetic Acid-enhanced MRI: a Classification Tree Analysis
verfasst von
Hyun Jeong Park
Kyung Mi Jang
Tae Wook Kang
Kyoung Doo Song
Seong Hyun Kim
Young Kon Kim
Dong Ik Cha
Joungyoun Kim
Juna Goo
Publikationsdatum
03.12.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 9/2016
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-015-4136-y

Weitere Artikel der Ausgabe 9/2016

European Radiology 9/2016 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.